Noonberg Sarah B.
SEC insider (Form 3/4/5 filer). CIK 0001706301. Director at Neurogene Inc. (NGNE) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Feb 20, 2026. Located in NEW YORK, NY.
Companies Noonberg Sarah B. has filed insider reports for
- Neurogene Inc. (NGNE): Director
- Metagenomi, Inc. (MGX): Officer, Chief Medical Officer
Noonberg Sarah B.
CIK: 0001706301
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (25.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (75.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 20, 2026NGNE
Neurogene Inc.
AwardDirectNon-Qualified Stock Option (right to buy)
12.1K shares- - Jun 12, 2025NGNE
Neurogene Inc.
AwardDirectNon-Qualified Stock Option (right to buy)
12.1K shares- - Jun 6, 2025MGX
Metagenomi, Inc.
SaleDirect5.2K shares at avg. $1.75$9K - Apr 1, 2025MGX
Metagenomi, Inc.
AwardDirect14K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 20, 2026 |  NGNE Neurogene Inc. | Award Non-Qualified Stock Option (right to buy) | 12,050 | - | - | Direct |
| Jun 12, 2025 | NGNE Neurogene Inc. | Award Non-Qualified Stock Option (right to buy) | 12,050 | - | - | Direct |
| Jun 6, 2025 |  MGX Metagenomi, Inc. | Sale | 5,239 | $1.75 | $9,168 | Direct |
| Apr 1, 2025 | MGX Metagenomi, Inc. | Award | 14,000 | - | - | Direct |
1-4 of 4 transactions